Update on the Principles and Novel Local and Systemic Therapies for the Treatment of Non-Infectious Uveitis

Author(s): Roberto Gallego-Pinazo, Rosa Dolz-Marco, Sebastian Martinez-Castillo, J. Fernando Arevalo, Manuel Diaz-Llopis

Journal Name: Inflammation & Allergy - Drug Targets (Discontinued)
Formerly Current Drug Targets - Inflammation & Allergy

Volume 12 , Issue 1 , 2013


Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrolimus in a third step; biological anti-TNF drugs in fourth position; and a last one with cyclophosphamide and chlorambucil. In the present review we go through the main characteristics and complications of all these treatments and make a rational of this five-step treatment protocol for non-infectious posterior uveitis.

Keywords: Anti-relapse treatment, biological therapies, immunosupressive treatment, intravitreal methotrexate, intravitreous corticosteroid deposits, non-infectious uveitis, therapeutic stages, anti-inflammatory, Immunosuppressive Drugs, chronic anti-relapse treatment

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 21 January, 2013
Page: [38 - 45]
Pages: 8
DOI: 10.2174/1871528111312010006

Article Metrics

PDF: 133